GPCR ligand binding
Roughly a third of approved drugs act on a GPCR.
Build a GPCR binding assay that measures ligand association and dissociation against the receptor.
Receptor ligand kinetics reveal selectivity and residence time, while membrane targets are harder to characterize. The inQuiQ supports GPCR ligand binding in lipid environments, with label-free analysis for GPCR binding and receptor binding kinetics.
Roughly a third of approved drugs act on a GPCR.
Build a GPCR binding assay that measures ligand association and dissociation against the receptor.
Characterize binding to channels and solute carriers.
Work with EGFR, HER2, and related receptors.
Measure antibody or ligand binding to the ectodomain and compare binding affinity and kinetics.
Measure engagement at the cell-surface receptor.
Compare candidate variants against the same receptor preparation.
Confirm that nanodisc reconstitution leaves the receptor still binding.
Check a new preparation before a larger campaign.
Discuss your assay with one of our application specialists.
Four independently addressable flow channels, each carrying four sensors, with the sample flowing through the channels in series.
Membrane proteins need a sensor surface built for them, either compatible with a lipid mono- or bilayer, or able to capture a nanodisc with the receptor still functional.
Expression yields for membrane proteins are usually low, so the binding response is small. Baseline noise sits at 0.1 RU RMS, and the sensor is regenerated between injections rather than replaced.
The sensorgram gives the full kinetics picture. Binding ffinity runs from 10 pM to 10 mM, with steady-state fitting where dissociation is too fast for kinetics.
Every measurement on a lipid bilayer sensor follows the same steps. The receptor is immobilized in a lipid bilayer on the sensor, the ligand flows past, and the response is recorded through the whole injection.
The receptor is delivered into a bilayer formed across the sensor.
For GPCR and membrane protein binding kinetics analysis, proteoliposomes fuse on the chip to leave a continuous supported bilayer over the waveguide, with the receptor sitting in it in native orientation.
Bare patches left in the layer are blocked before the first ligand sample arrives.
Defects expose the surface underneath, and detergent, free lipid, and buffer components adsorb there readily. That appears in the sensorgram as non-specific binding rather than as receptor engagement.
The ligand flows across the surface and the response climbs.
The association phase gives the on-rate, ka, for receptor-ligand binding. A reference channel carrying a protein-free bilayer of the same lipid composition separates ligand binding from binding to the membrane itself.
Buffer replaces the ligand and the response falls as the complex comes apart.
The dissociation phase gives kd, and 1/kd gives residence time, the number that separates two GPCR ligands sharing a KD. Single-cycle kinetics runs the series uninterrupted when the preparation is scarce.
A mild regeneration buffer returns the sensor to baseline for the next ligand.
The bilayer and the receptor in it stay intact, so every ligand meets the same surface. Conditions are kept gentle, since the lipid environment is what makes the measurement worth having.
Six capabilities, one modular benchtop instrument, in a label-free workflow.
Four channels with in-flow immobilization, or sixteen sensors with a spotter, compare constructs and controls from one injected sample.
Baseline noise stays low enough that a small binding response is still readable.
One affinity range covers weak modulators through tight ligands, with kon and koff from the same injection series.

Sensor surfaces compatible with lipid mono- and bilayers, or able to capture nanodiscs, keep the receptor functional.
The temperature-controlled flow cell holds conditions steady while a fragile preparation is measured over many injections.
Simply add an autosampler, and run a long construct or condition series unattended.
Capture the receptor on a lipid-compatible sensor surface, or capture the nanodisc carrying it, then inject the ligand across a concentration series. The association phase gives kon, the dissociation phase gives koff, and the two together give KD. Affinity on the inQuiQ runs from 10 pM to 10 mM.
Keep it in a lipid environment. Detergent micelles, nanodiscs, and SMALPs all preserve the folded receptor, and the sensor surface has to suit them. A standard hydrogel chip does not, so membrane work uses a surface built for lipid mono- and bilayers or for nanodisc capture.
Yes, on a label-free biosensor with a sensor surface designed for it. The particle is captured through a tag on the receptor or on the scaffold, and the ligand is then injected over it. A reference channel carrying empty particles separates binding to the receptor from binding to the lipid or the scaffold.
The inQuiQ runs from 30 µL of sample per injection. Sensors are regenerable, so one prepared surface carries a series of ligands, concentrations, and controls rather than one measurement per surface. That matters when expression yield is the limit on the experiment.
Affinity (KD) says how tightly ligand and receptor bind at equilibrium. Kinetics says how they get there: kon for how fast the complex forms, koff for how fast it falls apart. A receptor ligand binding assay reported as KD alone hides that, because two ligands with the same KD can have very different residence times.
